Response to Petri: Can a proteomics strategy be used to identify the anti-malarial activity of chloroquine?

Trends in Pharmacological Sciences

Volumn 24, Issue 5, 2003, Pages 212-213

  Haystead, Timothy A J ^a,b  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Serenex Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE DEHYDROGENASE; CHLOROQUINE; ENZYME; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ANTIMALARIAL ACTIVITY; ARTHRITIS; AUTOIMMUNE DISEASE; BLINDNESS; CELL PROTECTION; DRUG MECHANISM; DRUG TARGETING; ERYTHROCYTE; MALARIA; MOLECULAR BIOLOGY; MONOCYTE; NONHUMAN; NOTE; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEOMICS; RETINOPATHY; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0037724019     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(03)00072-5     Document Type: Note

References (6)

1. Venter J.C., et al. The sequence of the human genome. Science. 291:2001;1304-1351.
2. Lander E.S., et al. Initial sequencing and analysis of the human genome. Nature. 409:2001;860-921.
3. Waterston R.H., et al. Initial sequencing and comparative analysis of the mouse genome. Nature. 420:2002;520-562.
4. Gardner M.J., et al. Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 419:2002;498-511.
5. Graves P.R., et al. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol. Pharmacol. 62:2002;1364-1372.
6. Petri, W.A. (2003) 'a proteomics strategy' be used to identify the anti-malarial activity of chloroquine? Trends Pharmacol. Sci. 24 Xref: doi:10.1016/S0165-6147(03)00071-3.